Physician profile
Roosevelt Daniel
NPI 1275571846
$5,140.78
in general payments reported to CMS, 2019-2025
26 companies · $1,730 in 2025
The $1,730 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $39.10 · 2021: $230 · 2022: $539 · 2023: $745 · 2024: $1,858 · 2025: $1,730.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,037 · Education: $296.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,037.07 |
| Education | $295.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,067.31 | 2022-2025 | Qulipta, Vraylar, Ubrelvy |
| Novo Nordisk INC | $984.31 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $881.62 | 2020-2025 | Farxiga, Airsupra, Breztri |
| Astellas Pharma US INC | $322.09 | 2024 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $320.25 | 2023-2025 | |
| Lilly USA, LLC | $256.94 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $221.54 | 2025 | Caplyta |
| Amgen INC. | $190.28 | 2024-2025 | Repatha, Otezla, Repatha |
| Merck Sharp & Dohme LLC | $155.02 | 2021-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Pfizer INC. | $109.75 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $88.22 | 2020-2025 | Jardiance |
| Exact Sciences Corporation | $72.33 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Hologic Sales and Service, LLC | $68.59 | 2021-2025 | Aptima, Thinprep 2000 Processor |
| Dexcom, INC. | $61.30 | 2021-2024 | Dexcom G6 Transmitter |
| Sanofi Pasteur INC. | $56.40 | 2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $51.67 | 2024 | |
| Glaxosmithkline, LLC. | $48.55 | 2021-2024 | Trelegy Ellipta |
| Seqirus USA INC | $42.84 | 2023-2024 | Flucelvax Quadrivalent, Fluad Quadrivalent, Flucelvax |
| Xeris Pharmaceuticals, INC. | $21.36 | 2023 | Gvoke Hypopen |
| Ironwood Pharmaceuticals, INC | $21.09 | 2024 | |
| Abbott Laboratories | $20.38 | 2023 | Infinity |
| Hikma Pharmaceuticals USA | $19.00 | 2024 | Ryaltris |
| Vanda Pharmaceuticals INC. | $17.35 | 2025 | Fanapt, Hetlioz |
| Corcept Therapeutics | $15.92 | 2024 | Korlym |
| Cranial Technologies, INC | $14.60 | 2022 | |
| Organon LLC | $12.07 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roosevelt Daniel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.